With diabetes costs taking double-digit increases--and expensive newer meds launching--insurers are tightening restrictions on drug use.
A time-honored technique for boosting drug sales is simple: Raise prices. Lately, plenty of drugmakers pressed by patent-cliff losses have done just that. But some notable price hikes on diabetes drugs may be backfiring with payers. With diabetes costs taking double-digit increases--and expensive newer meds launching--insurers are tightening restrictions on drug use.
Of course, the growing diabetes epidemic has helped push expenses upward. But price increases on drugs and devices are fueling the rise, too, AIS Health reports. Spending on diabetes meds grew by 10.4% last year, mainly because of an 11% hike in drug prices. In fact, the diabetes category accounts for the biggest expense growth of any traditional drug class, a Prime Therapeutics report states.
BlueCross BlueShield of Tennessee tells AIS Health that on a per-member basis, its diabetes treatment costs have grown by 33% from the first quarter of 2013 to the first quarter of 2014. Tops on its radar are price hikes on insulin drugs, notably Sanofi's ($SNY) Lantus, but the plan is seeing price increases on non-insulin brands, too. Even the prices on generics are going up, some payers say.
Read the full story here:
Source: Fierce Pharma
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More